Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Lowered by Zacks Research

Monte Rosa Therapeutics (NASDAQ:GLUE) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. raised their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Guggenheim upped their price target on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.33.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $24.40 on Monday. The stock has a market capitalization of $2.06 billion, a P/E ratio of -16.49 and a beta of 1.56. The business has a 50 day simple moving average of $19.52 and a 200 day simple moving average of $18.98. Monte Rosa Therapeutics has a one year low of $4.12 and a one year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Equities analysts expect that Monte Rosa Therapeutics will post -1.23 earnings per share for the current year.

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, Director Anthony M. Manning sold 10,000 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $23.11, for a total transaction of $231,100.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at approximately $231,100. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Filip Janku sold 5,407 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $24.50, for a total value of $132,471.50. Following the completion of the transaction, the insider owned 60,612 shares in the company, valued at $1,484,994. This represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 87,623 shares of company stock valued at $1,871,979. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its holdings in Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC bought a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $18,399,000. AQR Capital Management LLC boosted its stake in shares of Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after buying an additional 1,054,406 shares during the last quarter. Braidwell LP purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at approximately $14,870,000. Finally, Vestal Point Capital LP bought a new stake in Monte Rosa Therapeutics during the third quarter worth $5,928,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.